Related Experiment Video
Updated: Jun 3, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Do we have enough data to confirm the link between antidiabetic drug use and cancer development?
Józef Drzewoski1, Agata Drozdowska, Agnieszka Sliwińska
1Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University of Lodz, Zgierz, Poland. jdrzew@poczta.onet.pl
Abstract:
Diabetes, especially type 2, is associated with higher risk of certain types of cancer. Potential mechanisms underlying increased cancer risk in diabetics remain unclear. Insulin resistance, hyperinsulinemia, oxidative stress, advanced glycation end products, and chronic low-grade inflammation have been suggested. Interestingly, recent epidemiological studies have also reported an association between cancer incidence and antidiabetic drug therapy. The available data, although inconclusive, may suggest higher cancer risk in patients treated with some hypoglycemic medications (e.g., insulin and sulfonylureas). On the other hand, metformin and rosiglitazone may inhibit cancer progression, especially in breast cancer. In this review, we aim to discuss the current knowledge about this important clinical issue.
Related Concept Videos
Psychoneuroimmunology: Diabetes and Cancer
Cancer Prevention
Some...
Oral Hypoglycemic Agents: Biguanides and Glitazones
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mutagenicity and Carcinogenicity
Treatment Resistant Cancers
